Garrett Gray - May 30, 2025 Form 4 Insider Report for Checkpoint Therapeutics, Inc. (CKPT)

Role
Chief Financial Officer
Signature
/s/ Garrett Gray
Stock symbol
CKPT
Transactions as of
May 30, 2025
Transactions value $
$0
Form type
4
Date filed
5/30/2025, 11:16 AM
Previous filing
Apr 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GRAY WILLIAM GARRETT Chief Financial Officer 95 SAWYER RD, SUITE 110, WALTHAM /s/ Garrett Gray 2025-05-30 0001692961

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CKPT COMMON STOCK Disposition pursuant to a tender of shares in a change of control transaction -1.45M -100% 0 May 30, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Garrett Gray is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.